Podcast: Play in new window | Download (Duration: 25:17 — 23.8MB) | Embed
Subscribe: Apple Podcasts | Spotify | Amazon Music | Android | Pandora | iHeartRadio | Blubrry | Podcast Index | Email | TuneIn | RSS | More
“Dr. Moody is a process-oriented drug developer and executive who has specialized in the study of aging and aging mechanisms for over a decade. Since 2013, Dr. Moody has successfully built Ichor Therapeutics from a living room start-up into a premier, vertically integrated research organization focused on drug discovery and development for pathways of aging. R&D initiatives that constitute Ichor’s portfolio companies span enzyme therapy (Lysoclear, Inc.), senolytics (FoxBio, Inc.), small molecule drug discovery (Antoxerene, Inc.), antibody mimetics (Auctus Biologics, Inc.), protein chemistry tools (RecombiPure, Inc.), contract research services (Icaria Life Sciences, Inc.) and a strategic investment fund (Grapeseed.Bio). Dr. Moody has received graduate-level training in medicine, business, and laboratory research. ” Source
Ichor Therapeutics
A vertically integrated pre-clinical contract research organization that broadly focuses on the study of aging and aging pathways. The company offers a number of services and programs to support its clients and strategic priorities. Ichor operates from its corporate offices and research laboratories in rural LaFayette, NY (just south of Syracuse). The company is eager to engage collaborators and clients in industry and academia who share its vision of delivering next generation therapies for the illnesses of aging.
Dr. Kelsey Moody
“Dr. Moody is a process-oriented drug developer and executive who has specialized in the study of aging and aging mechanisms for over a decade. Since 2013, Dr. Moody has successfully built Ichor Therapeutics from a living room start-up into a premier, vertically integrated research organization focused on drug discovery and development for pathways of aging. R&D initiatives that constitute Ichor’s portfolio companies span enzyme therapy (Lysoclear, Inc.), senolytics (FoxBio, Inc.), small molecule drug discovery (Antoxerene, Inc.), antibody mimetics (Auctus Biologics, Inc.), protein chemistry tools (RecombiPure, Inc.), contract research services (Icaria Life Sciences, Inc.) and a strategic investment fund (Grapeseed.Bio). Dr. Moody has received graduate-level training in medicine, business, and laboratory research. ” Source
“Business units: (1) enzyme therapy (Lysoclear, Inc.), (2) senolytics (FoxBio, Inc.), (3) small molecule drug discovery (Antoxerene, Inc.), (4) antibody mimetics (Auctus Biologics, Inc.), (5) protein chemistry tools (RecombiPure, Inc.), (6) contract research services (Icaria Life Sciences, Inc.), and (7) a strategic investment fund (Grapeseed.Bio)
Responsibilities: Raised >$20M in funding to grow company from living room start-up to GXP facility with >40 employees. Designed and supervised buildout of four wet lab facilities (current facilities ~13,000 ft2 including SPF vivariums suitable for SCID work). Managed client relations, investor relations, and operating budgets >$7M. Built and worked with interdisciplinary teams to set translational plans for portfolio companies. Implemented GXP processes. Designed and executed numerous sponsored research projects. Managed collaborations with 3rd party companies, foundations, and academic institutions. Negotiated contracts with clients and licensing agreements with foundations and universities. Mentored and incubated visiting scientists and other start-up companies. Served on several advisory boards for companies, universities, non-profits, and investment funds” Source
Links